Education
About Us
Working with TipRanks
Follow Us
Oncolys BioPharma, Inc. (JP:4588)
:4588
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥458.00 - ¥2,548.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥71.68B
Enterprise Value¥55.66B
Total Cash (Recent Filing)¥1.39B
Total Debt (Recent Filing)¥377.04M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.37
Shares Outstanding29,291,600
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthImproved debt-to-equity (~0.12) and a meaningful rise in equity and assets provide durable funding capacity. A stronger balance sheet reduces near-term solvency risk and supports continued R&D and clinical programs without immediate liquidity distress, extending runway.
Specialized R&D FocusA clear strategic focus on oncolytic virus therapies and novel oncology modalities gives the company durable scientific differentiation. This niche expertise increases long-term licensing, partnership and high-unmet-need commercialization optionality if clinical progress continues.
High Gross Margin ProfilePositive gross profit and an unusually high gross-profit-to-revenue ratio in 2024 imply low direct costs. If revenues scale, the business model could deliver high incremental margins and convert revenue growth into contribution quickly, improving operating leverage long term.
Bears Say
Collapsing RevenueA multi-year collapse in revenue sharply reduces internal funding for trials and commercialization. Loss of scale undermines operating leverage, makes cost absorption harder, and leaves the company dependent on external capital or partnerships to sustain development over the next several quarters.
Persistent Cash BurnConsistent, large operating cash outflows and worsening free cash flow indicate the business is not self-funding. This sustained burn requires recurring external financing, raising dilution and financing-risk over time and constraining discretionary R&D or trial expansion.
Ongoing Losses / Negative ROEMaterial operating and net losses have produced negative ROE over multiple years, signaling structural unprofitability. Continued erosion of equity value heightens solvency and dilution risk and undermines investor returns absent a substantial revenue inflection or cost reset.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥458.00 and its highest was ¥2548.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥71.68B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is May 08, 2026 which is in 77 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on Feb 06, 2026. The company reported -¥15.37 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.37.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,291,600 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥15.37 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.343%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Technical Analysis
RaQualia Pharma Inc.
―
Chiome Bioscience Inc.
―
StemRIM Inc.
―
CellSource Co., Ltd.
―
STELLA PHARMA CORPORATION
―